AbbVie (NYSE: ABBV) today announced new Phase 3 data on a fixed-duration venetoclax-based combination at the European Hematology Association (EHA) 2026 Congress taking place June 11-14 in Stockholm, ...
New findings presented at ASCO 2026 show that a CAR-T cell therapy called Breyanzi (lisocabtagene maraleucel) is producing ...
Clinical trial data demonstrate that Cavhanza can be taken with or without food, offering patients greater administration convenience.
Enliven Therapeutics (ELVN) stock jumps as the company posts updated data from an early-stage trial for its lead asset ...
Treatment with so-called BTK inhibitors has improved the prognosis for people with chronic lymphocytic leukemia (CLL). At the same time, these drugs affect the immune system and may cause side effects ...
A cancer survivor marked one year since his bone marrow transplant by skydiving in Jackson on Saturday.
Chronic lymphocytic leukemia (CLL) treatment options depend on your diagnosis. In earlier stages, “watchful waiting” may be recommended. More advanced CLL may require a combination of therapies.
Poster presentations from ongoing clinical trials of two core assets, olverembatinib and lisaftoclax, highlight global innovation capabilities in ...
The chronic phase is the first and most treatable phase of chronic myeloid leukemia. It is characterized by a low percentage of abnormal cells in the blood and bone marrow. With treatment, most people ...
The company has launched a generic version of Pfizer's Bosulif for chronic myeloid leukaemia and secured 180 days of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results